Angioplasty, Myocardial Infarction, Percutaneous Coronary
Conditions
Keywords
Myocardial Infarction, Coronary Angioplasty, Myocardial infarction, Angioplasty, Transluminal, Percutaneous Coronary
Brief summary
Although statin prior to PCI has favorable effects in stable angina and ACS except ST elevation MI (STEMI), there have been few studies for STEMI. Celik T et al. reported in patients with STEMI that prior statin use may improve coronary blood flow after PCI in patients with AMI, possibly by its beneficial effects on microvascular function. But this study was retrospective, non-randomized study and evaluated the effects for chronic statin therapy not acute high dose effect. Therefore, the investigators investigated whether acute high-dose statin prior to primary PCI in ST segment elevation myocardial infarction can have beneficial effect or not for periprocedural period and 30 days-cardiac events.
Interventions
DRUGAtorvastatin
Atorvastatin 10 mg vs. 80 mg before intervention
Sponsors
Yonsei University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. The patient must be at least 18 years and 80 years of age. 2. The patient had the symptoms of acute myocardial infarction within 12 hours with ST segment elevation of more than 1 mm in at least two contiguous leads of EKG or new onset LBBB. 3. The patient or guardian agrees to the study protocol and provides informed, written consent.
Exclusion criteria
1. Patients to whom PCI can not be undergone within 12 hours from receiving the study drug 2. Cardiogenic shock or symptomatic hypotension or sitting SBP \< 95 mmHg 3. The history of major surgery, trauma, retinal hemorrhage, significant gastrointestinal or genitourinary bleeding within recent 6 weeks; history of cerebrovascular attack within two years, or cerebrovascular attack with a significant residual neurological deficit 4. History of cerebrovascular attack within two years, or cerebrovascular attack with a significant residual neurological deficit 5. Severe or malignant hypertension (= sitting SBP \> 180 mmHg and/or sitting DBP \> 105 mmHg) 6. The history or diagnosis of vasculitis; renal insufficiency (the level of serum creatinine is two times higher than the upper limit of normal of each center) 7. The patients who might die of other disease than cardiac disease during the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the effect of high dose atorvastatin in STEMI - 30 Days MACE(death, myocardial infarction, target vessel revascularization) | 30 days |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the safety of high dose atorvastatin in STEMI - TIMI flow at before and after PCI - Myocardial blush grade after PCI - Procedural success (No reflow incidence) - MACE at 6 month - Periprocedural MI | immediate, 30 days, 6 months |
Countries
South Korea
Outcome results
None listed